CD32b
Showing 1 - 25 of >10,000
B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia Trial in United Kingdom (BI-1206 single agent dose
Completed
- B-cell Lymphoma
- +2 more
- BI-1206 single agent dose escalation phase
- +3 more
-
Leicester, England, United Kingdom
- +4 more
Jun 17, 2021
Healthy Subjects Trial in Baltimore (MGD010, Placebo, Hepatitis A vaccine)
Completed
- Healthy Subjects
- MGD010
- +2 more
-
Baltimore, MarylandPAREXEL Baltimore Early Phase Clinical Unit
Feb 4, 2022
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,
Recruiting
- HER2-positive Breast Cancer
- +4 more
-
Essen, Germany
- +5 more
Nov 15, 2022
Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)
Recruiting
- Indolent B-Cell Non-Hodgkin Lymphoma
- BI1206
-
Atlanta, Georgia
- +8 more
Mar 1, 2022
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
B-cell NHL, CLL Trial (CARCIK-CD19)
Not yet recruiting
- B-cell NHL
- CLL
- CARCIK-CD19
- (no location specified)
May 19, 2023
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- P-CD19CD20-ALLO1
- Rimiducid
-
La Jolla, California
- +7 more
Aug 25, 2023
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)
Recruiting
- B-Cell Leukemia
- +2 more
- Anti-CD19 Autologous CAR-T Cell Infusion
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
HBV Reactivation in Anti CD20 Treatment
Active, not recruiting
- Hepatitis B
-
Afula, Tsafon, IsraelHaEmek Medical Center
Mar 14, 2023
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle
Terminated
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +5 more
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 1, 2022